PIK3CD and diffuse large B-cell lymphoma: A trial of the pan-PI3K inhibitor BKM-120 in relapsed/refractory non-Hodgkin lymphoma yielded a 12% objective response rate in DLBCL, but the subtype of the DLBCL tumors was not investigated [22].